Every 8-K that Petvivo Hldgs Inc (PETV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PETV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PETV filings page.
PetVivo Holdings, Inc. (PETV) announced that its representatives plan to use an updated investor presentation in meetings with investors, analysts and at conferences. The presentation, dated August 2026, is furnished as Exhibit 99.1 to this current report.
The company states that this information is being provided under Regulation FD and Item 7.01 and is considered "furnished," not "filed," which limits potential liability under the Exchange Act and affects incorporation by reference into other securities filings. PetVivo may update or modify the presentation over time, including through future SEC reports, press releases or its corporate website.
PetVivo Holdings, Inc. terminated its Exclusive License and Supply Agreement with VetStem, Inc. for the PrecisePRP® product line through a Termination and Settlement Agreement effective July 24, 2026. All exclusive rights under the prior license reverted to VetStem, remaining PrecisePRP® inventory transferred to VetStem, and the parties exchanged mutual releases covering substantially all claims arising under the license, fully resolving related disputes.
Under the settlement, PetVivo’s sole stated financial obligation is aggregate cash payments of $75,000, with $50,000 due within 14 days of the effective date and $25,000 due within 30 business days, plus any additional amount that may arise from an inventory reconciliation mechanism. A warrant held by VetStem to purchase 250,000 PetVivo common shares remains outstanding on its existing terms. The company states that this resolution allows it to concentrate resources on its proprietary technologies, including SPRYNG® with OsteoCushion® Technology, and broader strategic initiatives.
PetVivo Holdings, Inc. reported a change in its independent auditors. Stephano Slack LLC resigned as the company’s independent registered public accounting firm, effective July 2, 2026, after auditing the fiscal years ended March 31, 2026 and March 31, 2025. Those audit reports contained no adverse or disclaimed opinions and were not qualified, but the 2026 report included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, which is treated as a reportable event. The company states there were no disagreements with Stephano Slack on accounting or auditing matters.
On July 23, 2026, with Audit Committee approval, PetVivo engaged GuzmanGray, A Professional Accountancy Corporation, as its new independent registered public accounting firm for the fiscal year ending March 31, 2027, including interim review periods ending June 30, September 30, and December 31, 2026. PetVivo reports it had not previously consulted GuzmanGray on accounting, auditing, or financial reporting issues.
PetVivo Holdings has signed an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM) in an all‑stock transaction. PBM will merge into a PetVivo subsidiary and, after closing, operate as a wholly owned subsidiary of Cosmeta Corp., PetVivo’s biomaterials-focused operating arm.
PBM shareholders are slated to receive an aggregate of 3,000,000 shares of PetVivo restricted common stock. A first block of up to 1,500,000 shares will be fully vested at closing, while the remaining “Milestone Shares” will be issued but subject to forfeiture unless specified development and regulatory milestones are achieved.
Before closing, PBM must clear defined liabilities and convert or settle all preferred stock, SAFEs, options, warrants and other securities. Closing also depends on PetVivo completing an equity financing with at least $5.0 million in gross proceeds. PBM’s extensive intellectual property portfolio will remain in PBM, and key PBM personnel are expected to stay involved through consulting and service arrangements.
PetVivo Holdings, Inc. received gross proceeds of $150,000 on June 8, 2026 from a partial exercise of an investor purchase option under a March 13, 2026 Subscription Agreement, bringing total equity financing in this unit Offering to $1,150,000.
The company has now issued 1,437,500 Units at $0.80 per Unit, including 187,500 Units in the latest tranche. Each Unit includes one common share and a warrant to buy one common share at $1.10 per share, exercisable immediately and expiring three years from issuance.
Earlier installments provided $400,000 on March 13, 2026 for 500,000 Units and $600,000 on April 15, 2026 for 750,000 Units. The investor may still purchase up to an additional $1,350,000 of Units, or 1,687,500 Units, through July 15, 2026 on substantially the same terms.
PetVivo Holdings, Inc. closed the final tranche of a private equity financing on April 15, 2026, receiving $600,000 and bringing the total investment under a Subscription Agreement to $1,000,000. The Company issued 1,250,000 units at $0.80 per unit, each unit containing one restricted common share and a warrant to buy one common share at $1.10. The warrants are exercisable immediately and expire three years from issuance. The investor also received an option to purchase up to an additional $1,500,000 of equity on similar terms, for up to 1,875,000 more units, which the Company anticipates could be funded on or before June 15, 2026. The transaction was structured as a private placement to an accredited investor under Section 4(a)(2) and Regulation D, and all securities issued are characterized as restricted.
PetVivo Holdings, Inc. entered into a Subscription Agreement for $1,000,000 of equity financing through 1,250,000 units priced at $0.80 per unit. Each unit includes one restricted common share and a warrant to buy one share at $1.10, exercisable immediately and expiring three years from issuance.
The company received $400,000 on March 13, 2026 and expects the remaining $600,000 by April 15, 2026. The investor also received an option to provide an additional $1,500,000 for 1,875,000 more units on the same terms, anticipated by June 30, 2026. The private placement was conducted under Section 4(a)(2) and Regulation D, with the investor representing accredited status, and all securities issued as restricted under Rule 144.
PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.
The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.
PetVivo Holdings, Inc. filed a current report to furnish an updated investor presentation under Regulation FD. Company representatives plan to use this presentation at investor conferences and other forums, and it is attached as Exhibit 99.1 and incorporated into the report by reference.
The investor presentation, dated March 2026, may also be used with investors, analysts and others and on the company’s website. The information is being furnished, not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into Securities Act or Exchange Act registration statements.
PetVivo Holdings, Inc. reported a change in its Board of Directors. On January 26, 2026, director Spencer Breithaupt resigned from the Board, effective that day. The company states his resignation was not due to any disagreement over operations, policies, or practices.
Following his departure, the Board reduced its size from seven to six directors and does not plan to immediately fill the vacancy, though it may add a seventh director in the future at its discretion. The Board expressed appreciation for Mr. Breithaupt’s leadership, guidance, and contributions during his service.
PetVivo Holdings, Inc. furnished a new investor presentation as part of a current report. Representatives plan to use this January 2026 presentation at investor conferences, in other forums, and on the company’s website.
The presentation is included as Exhibit 99.1 and is furnished under Regulation FD and Item 7.01, meaning it is not deemed filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced. Management notes that the information is summary in nature and may be updated over time through future SEC reports, press releases, or other public disclosures.
PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings, Inc. converted outstanding shareholder debt into equity. Effective as of September 30, 2025, four shareholders holding fourteen promissory notes with an aggregate outstanding amount of $2,018,155, including $1,850,000 of principal and $168,155 of accrued interest, agreed to convert their notes into 3,669,806 shares of PetVivo common stock. The effective conversion prices ranged from $0.50 to $0.75 per share, and the notes were fully converted, treated as paid in full, and cancelled once the shares were issued.
The shares issued are restricted securities, relying on an exemption from registration under Section 4(a)(2) of the Securities Act. The lenders represented that they are accredited investors acquiring the shares for investment, and the stock certificates bear a legend stating that the securities are restricted and cannot be sold or transferred without registration or an applicable exemption.